From left to right: Vittoria Bocchi, Melissa Yao, Julia Brunner, Tzippora Chwat-EdelsteinVittoria Bocchi, Julia Brunner, Melissa Yao, and Tzippora Chwat-Edelstein, four Sloan Kettering Institute researchers, were named 2024 Marie-Josée Kravis Women in Science Endeavor, or Kravis WiSE, fellowship grant recipients.
Twelve graduate students were named recipients of the Fred Hutchinson Cancer Center 2024 Harold M. Weintraub Graduate Student Award, which recognizes exceptional achievement in graduate studies in the biological sciences.
The Medical College of Wisconsin faculty, researchers, staff, and students were invited to sign a construction beam that will soon become a permanent fixture of the new MCW Cancer Research Building.
An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center showed for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.
University of Cincinnati Cancer Center researchers in the lab of Jun-Lin Guan have identified a protein that helps prevent metastasis of HER2-positive breast cancer. About 20% of breast cancer patients are HER2-positive, and these cancers tend to be more aggressive than other types.
A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin, or BCG, the vaccine for tuberculosis, reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.
FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor, or EGFR, exon 20 insertion mutations, as detected by an FDA-approved test.
FDA approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.
FDA granted accelerated approval to Brukinsa (zanubrutinib) with obinutuzumab for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
